US20060168665A1 - Flourescent proteins as cell type specific reporters - Google Patents
Flourescent proteins as cell type specific reporters Download PDFInfo
- Publication number
- US20060168665A1 US20060168665A1 US11/293,932 US29393205A US2006168665A1 US 20060168665 A1 US20060168665 A1 US 20060168665A1 US 29393205 A US29393205 A US 29393205A US 2006168665 A1 US2006168665 A1 US 2006168665A1
- Authority
- US
- United States
- Prior art keywords
- cells
- cell
- promoter
- fluorescent protein
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 11
- 102000004169 proteins and genes Human genes 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 42
- 102000034287 fluorescent proteins Human genes 0.000 claims abstract description 22
- 108091006047 fluorescent proteins Proteins 0.000 claims abstract description 22
- 238000011161 development Methods 0.000 claims abstract description 21
- 238000004113 cell culture Methods 0.000 claims abstract description 18
- 108020004414 DNA Proteins 0.000 claims abstract description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 14
- 239000000126 substance Substances 0.000 claims abstract description 11
- 230000002110 toxicologic effect Effects 0.000 claims abstract description 11
- 231100000027 toxicology Toxicity 0.000 claims abstract description 11
- 230000001419 dependent effect Effects 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 111
- 239000005090 green fluorescent protein Substances 0.000 claims description 41
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 40
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 39
- 230000014509 gene expression Effects 0.000 claims description 34
- 230000004069 differentiation Effects 0.000 claims description 20
- 210000002064 heart cell Anatomy 0.000 claims description 16
- 102000007469 Actins Human genes 0.000 claims description 14
- 108010085238 Actins Proteins 0.000 claims description 14
- 238000012360 testing method Methods 0.000 claims description 8
- 230000001747 exhibiting effect Effects 0.000 claims description 6
- 210000002569 neuron Anatomy 0.000 claims description 5
- 239000013612 plasmid Substances 0.000 claims description 5
- 210000002363 skeletal muscle cell Anatomy 0.000 claims description 5
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 5
- 210000003321 cartilage cell Anatomy 0.000 claims description 4
- 210000002889 endothelial cell Anatomy 0.000 claims description 4
- 210000002919 epithelial cell Anatomy 0.000 claims description 4
- 210000002950 fibroblast Anatomy 0.000 claims description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 4
- 210000004498 neuroglial cell Anatomy 0.000 claims description 4
- 241000283984 Rodentia Species 0.000 claims description 3
- 101150114527 Nkx2-5 gene Proteins 0.000 claims description 2
- 101100460507 Xenopus laevis nkx-2.5 gene Proteins 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 210000001671 embryonic stem cell Anatomy 0.000 claims 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 108091005948 blue fluorescent proteins Proteins 0.000 claims 1
- 238000012835 hanging drop method Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 108010054624 red fluorescent protein Proteins 0.000 claims 1
- 230000018109 developmental process Effects 0.000 abstract description 16
- 230000009261 transgenic effect Effects 0.000 abstract description 7
- 238000012258 culturing Methods 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000023715 cellular developmental process Effects 0.000 abstract description 3
- 210000004413 cardiac myocyte Anatomy 0.000 description 21
- 238000004520 electroporation Methods 0.000 description 12
- 238000010009 beating Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 238000007747 plating Methods 0.000 description 6
- 210000002242 embryoid body Anatomy 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- 229930193140 Neomycin Natural products 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 238000000799 fluorescence microscopy Methods 0.000 description 4
- 229960004927 neomycin Drugs 0.000 description 4
- 238000010187 selection method Methods 0.000 description 4
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001000104 Homo sapiens Myosin-11 Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100036639 Myosin-11 Human genes 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000011207 functional examination Methods 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000012402 patch clamp technique Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Definitions
- the present invention relates to the use of non-cell-damaging fluorescent proteins as cell-type specific reporters.
- the invention relates to non-human mammal embryonic stem (ES) cells stably transfected with a DNA construct comprising a DNA sequence coding for a non-cell-damaging fluorescent protein and a cell- and/or development-dependent promoter operably linked with said DNA sequence; a method for preparing such ES cells; a cell culture obainable by culturing said ES cells; a method for the toxicological examination of substances using such cell cultures; a method for producing transgenic non-human mammals using said ES cells; a transgenic non-human mammal obtainable by said method; and a method for examining stages of cellular development using cells of such a non-human mammal.
- ES mammal embryonic stem
- Embryonic stem (ES) cells both are the basis of the creation of transgenic animal models and can be used for in vitro cell culture systems.
- the cell types differentiating from ES cells have been identified by characterizing them by antibody staining or by in situ hybridization with antisense oligonucleotides.
- the cells had to be fixed first. None of the prior art methods are suitable for subsequent functional studies with the different cell types differentiated from ES cells.
- the only method for performing functional studies on ES-cell derivatives in vivo has been morphological identification. It has been successful, although very unsatisfactorily, with cardiac and skeletal muscle cells because they were characterized by contractions. Already with the non-contracting ventricular cells, recognition for functional studies was difficult.
- ES cells of cell line D3 are differentiated into cardiomyocytes under the following cell culture conditions: The cells are placed in a hanging drop for 2 days, then kept in suspension for 5 days and subsequently plated (Maltsev et al., 1994, Circ.
- EBs extracellular body cells
- enzymatic digestion collagenase
- these cardiomyocytes are accessible to functional, molecular-biological and morphological (immune histochemistry, electron microscopy) examination techniques during the various differentiation stages.
- the thus generated EBs also include, inter alia, neurons, glia cells, hematopoietic cells, endothelial cells (early capillary), smooth muscle cells, skeletal muscle cells, cartilage cells, fibroblasts and epithelial cells.
- GFP Green Fluorescent Protein
- Cardiovascular diseases are still among the most frequent causes of death in the Western industrial countries. Only through intensive basic research in this field, the pathophysiological causes can be found, and new therapeutic approaches can be devised, and toxicological changes described. For studying the pathogenesis of cardiovascular diseases and for testing new pharmacological and toxicological substances, models are needed which, on one hand, can be transferred to humans and, on the other hand, can replace the tedious and cost-intensive animal models. Still in the year 1991, over 2 million animals have been employed for animal experiments in the federal states of the former Western Germany alone.
- cardiomyocytes One starting point of pharmacological/toxicological research which has recently grown more and more important is heart differentiation. From the stereotypically proceeding heart cell development, conclusions can be drawn to pathological and toxicological changes of cardiomyocytes. Thus, for example, it is known that the receptor state and the intracellular signal cascades are disturbed in cardiac hypertrophy (Yamazaki et al., J. Mol. Cell Cardiol. 27(1): 133-140 (1995)) and heart insufficiency (Johnson et al., Biochem. Pharmacol. 45(12): 2365-2372 (1993)). These pathologically altered cardiomyocytes are in part again similar to heart cells of early differentiation stages.
- ES cells can be stably transfected, using electroporation, with a DNA construct in which a gene coding for a non-cell-damaging fluorescent protein is coupled with a cell- and development-dependent promoter.
- This construct is integrated in the native DNA. After the specific activation of intracellular signals, the promoter is activated and the fluorescent protein expressed.
- ES cells which activate a cell-specific transcription factor at a certain point of differentiation could be recognized by their fluorescence emissions when being under fluorescent excitation.
- the present invention relates to non-human mammal embryonic stem (ES) cells stably transfected with a DNA construct comprising
- the ES cells are preferably derived from rodents, especially mice. Particularly preferred ES cells are D3 cells (Doetschmann et al., J. Embryol. Exp. Morphol. 87, 27 (1985)), R1 cells (Nagy et al., PNAS (1995)), E14 cells (Handyside et al., Roux Arch. Develop. Biol. 198, 48 (1989)), CCE cells (Bradley et al., Nature 309, 255 (1985)) and P19 cells (Mummery et al., Dev. Biol. 109, 402 (1985)).
- the Green Fluorescent Protein from the jellyfish Auequorea victoria (described in WO-A-95/07463, WO-A-96/27675 and WO-A-95/21191) and its derivatives “Blue GFP” (Heim et al., Curr. Biol. 6(2): 178-182 (1996)) and “Redshift GFP” (Muldoon et al.; Biotechniques 22(1): 162-167 (1997)).
- GFP Green Fluorescent Protein
- the green fluorescent GFP especially the GFP mutant contained in the deposited strain DSM 11633.
- the term “cell- and/or development-dependent promoter” is intended to mean a promoter which displays its promoter activity only in particular cell types and/or only in particular stages of cellular development, both in cell cultures (embryoid bodies) and in transgenic non-human mammals dervied from the ES cells according to the invention.
- any other known cell-specific promoter can be employed, e.g., for nerve cells, heart cells, neurons, glia cells, hematopoietic cells, endothelial cells, smooth muscle cells, skeletal muscle cells, cartilage cells, fibroblasts and epithelial cells.
- the promoter is a promoter specific for heart cells.
- the following promoters may be mentioned: SMHC Minimal Promoter (specific for smooth muscle cells, Kallmeier et al., J. Biol. Chem. 270(52): 30949-30957 (1995)); Nkx-2.5 (specific for very early cardiomyocytes, Lints et al., Development, 119(2): 419-431 (1993)); human ⁇ -actin (specific for cardiac tissue, Sartorelli et al., Genes Dev., 4(10): 1811-1822 (1990)); MLC-2V (specific for ventricles, O'Brien et al., Proc. Natl. Acad. Sci. USA, 90(11): 5157-5161 (1993) and WO-A-96/16163.
- the DNA construct includes further functional DNA sequences, especially enhancers and selective sequences.
- selective sequences include, e.g., neomycin and hygromycin.
- the invention further relates to a method for preparing the ES cells according to the invention, comprising:
- Said introducing may be effected by any method known to those skilled in the art. However, electroporation is preferred.
- the screening is preferably performed using the selective sequences present in the DNA construct.
- the invention also relates to the above described DNA construct.
- Preferred constructs are the reporter constructs pCX-( ⁇ -act)GFP-Neo and pCX-( ⁇ -act)GFP-Neo (DSM 11633) as depicted in FIGS. 1 and 2 .
- the invention also relates to a cell culture exhibiting cell-type specific expression of a non-cell-damaging fluorescent protein, obtainable by culturing the ES cells according to the invention.
- the cells are in the form of aggregates (embryoid bodies).
- standard methods are followed, e.g., the “hanging drop” method or methylcellulose culture (Wobus et al., Differentiation (1991) 48, 172- 182).
- an exact cell typing can be performed for the first time in vivo in the whole animal.
- fluorescent heart cells should be observed already in the early primordiums of the embryos, which would enable an in vivo observation of the development of the heart in the early embryonic stage.
- the heart cells could be easily identified thereby in different stages of development.
- FIG. 1 shows the reporter gene construct pCX-( ⁇ -act)GFP-Neo used in Example 1.
- FIG. 2 shows the reporter gene construct pCX-( ⁇ -act)GFP-Neo (DSM 11633) used in Example 2.
- FIG. 3 Part A: Two young EBs are shown in suspension under transmitted light (Aa) and under 488 nm excitation (Ab). Since heart cells have not yet differentiated in these early EBs, a green fluorescence cannot be seen.
- Part B EB after 3 days of plating (7+3 days) under transmitted light (Ba), under 488 nm fluorescence excitation (Bb) and in a combination of transmitted light and 488 nm fluorescence excitation.
- Ba transmitted light
- Bb 488 nm fluorescence excitation
- a relatively small spontaneously beating area could be observed. This corresponds to the portion of the EB exhibiting spontaneous contractions.
- the EBs were imaged with 20 ⁇ magnification.
- FIG. 4 shows distribution histograms of cells from EBs established by the FACS method, obtained from ES cells with pCX-( ⁇ -act)GFP-Neo. The construct was linearized using AatI so that the CMV-IE enhancer was destroyed.
- a SalI-XbaI restriction fragment containing a neomycin (G418) resistance gene of pTL2Neo (supplied by Dr. Tarakhovsky) was inserted into the SalI site of pCX-GFP by ligation with blunt ends.
- the resulting construct pCX-( ⁇ -act)GFP-Neo ( FIG. 1 ) was used for the electroporation of D3 cells.
- the cell suspension was placed on ice for 20 min and then transferred to a 10 cm tissue grade Petri dish with a G418 resistance feeder layer in 10 ml of DMEM medium with 15% FCS (fetal calf serum). Two days later, 300 ⁇ g/ml neomycin (G418, Gibco) was added to select G418-resistant cells. The medium with G418 (300 ⁇ g/ml) was exchanged every other day. After 8 to 10 days of selection, drug-resistant colonies appeared which were tested for GFP expression by fluorescence microscopy.
- EBs were developed according to the standard “hanging drop” method (A. Wobus, G. Walluka and J. Hescheler; Differentiation (1991) 48, 173-182).
- the EBs derived from ES cells having an integrated GFP expression vector under the control of the M-actin promoter exhibited an intense green luminosity under the fluorescence microscope.
- the GFP expression was distributed in unequal proportions among different cell types which appeared in the course of differentiation.
- the brightest green luminosity in EBs after the occurrence of contractile myocardiocytes coincides with corresponding beating regions rathr than beating core parts (central parts) of EBs.
- EBs were differentiated using collagenase and plated onto slides and then cultured for 2-3 days after which electrophysiological measurements were made according to the standard procedure (V. Maltsev, A. Wobus, J. Rohwedei, M. Bader and J. Hescheler, Circ. Res. (1994) 75(2), 233-244).
- Isolated spontaneously beating cardiomyocytes which strongly express GFP have all the electrophysiological properties typical of cardiomyocytes including action potentials, Ca 2+ , Na + , K + and I f flows, which was shown by the patch-clamp technique.
- stable ES cell lines which are strongly expressing GFP due to an expression vector integrated in the genome can differentiate into functionally mature contractile cardiomyocytes which have the same basic electro-physiological properties as cardiomyocytes which have differentiated from “normal” D3 cells.
- the pCX-GFP expression vector (see Example 1) was cleaved with the restrictases SnaBI and ApaI to excise the chicken ⁇ -actin promoter. Subsequently, the above mentioned SalI-HindIII fragment of the heart-specific ⁇ -actin promoter was inserted by ligation with blunt ends.
- the restrictases Tth111I, SalI and HinfI were used to select plasmid clones in which the heart-specific ⁇ -actin promoter had been inserted in the right orientation with respect to the GFP-coding sequence.
- a neomycin (G418) resistance gene as described in Example 1a) was then inserted in the SalI site, and the resulting plasmid pCX-( ⁇ -act)GFP-Neo ( FIG. 2 ) was used for the electroporation of D3 cells.
- Electroporation and selection procedure The pCX-( ⁇ -act)GFP-Neo was linearized with ScaI (outside the GFP expression cassette, as described in Example 1b)) or AatI to destroy the cytomegalovirus (CMV-IE) enhancer (see below). The electroporation and the G418 selection procedure were performed as described in Example 1b).
- EBs were developed as described in Example 1c).
- ES cells bearing the pCX-( ⁇ -act)GFP-Neo integrated in the genome exhibit no or only a very weak signal which is visible by fluorescence microscopy.
- the FACS analysis shows that the average level of the green fluorescence of D3 cells containing pCX-( ⁇ -act)GFP-Neo linearized by SacI is about 35 to 40 times lower than for cell lines bearing pCX-( ⁇ -act)-GFP-Neo.
- the beating regions which occurred 2 to 4 days after plating the EBs show a green luminosity visible by fluorescence microscopy at a level comparable to that of the GFP expression in ES cells bearing pCX-( ⁇ -act)GFP-Neo.
- the beating regions consisting of functionally mature cardiotyocytes are merely regions having an intense visible luminosity among other cell types in developing EBs. By daily monitoring, it is possible to detect separated luminous regions 1 to 1.5 days before they start to beat.
- the heart-specific character of GFP expression was confirmed by ⁇ -actin specific immunostaining of single cells, which correlates with the GFP expression under the control of the heart-specific ⁇ -actin promoter.
- the G418-resistant clones showed a much higher diversification of the initial GFP expression than was shown by clones with an intact CMV-IE enhancer.
- Several ES clones with the lowest “background” were selected by FACS screening. These clones have an about 5 times lower initial fluorescence intensity and may be comparable with cells of the negative control (wild type) without a GFP vector.
- FACS analysis exhibited a high resolution between cells having entered heart-specific differentiation and the remainder of the cell population which showed, the pronounced one-to-two peak character of histogram dynamics during the EB development ( FIG. 4 ).
- the described approach allows to examine the differentiation of ES cells into cardiomyocytes “in vitro”, the GFP expression vector with the heart-specific promoter being used as a “living” reporter-gene system which renders cells in the early stages of development discernible.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
- The present invention relates to the use of non-cell-damaging fluorescent proteins as cell-type specific reporters. In detail, the invention relates to non-human mammal embryonic stem (ES) cells stably transfected with a DNA construct comprising a DNA sequence coding for a non-cell-damaging fluorescent protein and a cell- and/or development-dependent promoter operably linked with said DNA sequence; a method for preparing such ES cells; a cell culture obainable by culturing said ES cells; a method for the toxicological examination of substances using such cell cultures; a method for producing transgenic non-human mammals using said ES cells; a transgenic non-human mammal obtainable by said method; and a method for examining stages of cellular development using cells of such a non-human mammal.
- Embryonic stem (ES) cells both are the basis of the creation of transgenic animal models and can be used for in vitro cell culture systems. To date, the cell types differentiating from ES cells have been identified by characterizing them by antibody staining or by in situ hybridization with antisense oligonucleotides. However, to do this, the cells had to be fixed first. None of the prior art methods are suitable for subsequent functional studies with the different cell types differentiated from ES cells. To date, the only method for performing functional studies on ES-cell derivatives in vivo has been morphological identification. It has been successful, although very unsatisfactorily, with cardiac and skeletal muscle cells because they were characterized by contractions. Already with the non-contracting ventricular cells, recognition for functional studies was difficult. Thus, in Maltsev et al., 1994, Circ. Res., 75, 233-244, and DD-299439 A5, a model is described in which the differentiation of heart cells (cardiomyocytes) takes place in vitro from a very early stage of development to a specialized pacemaker, ventricular or atrial heart cell (Maltsev et al., 1994, Circ. Res., 75, 233-244). For this purpose, totipotent embryonic stem (ES) cells of cell line D3 are differentiated into cardiomyocytes under the following cell culture conditions: The cells are placed in a hanging drop for 2 days, then kept in suspension for 5 days and subsequently plated (Maltsev et al., 1994, Circ. Res., 75, 233-244). Within 1-2 days from the plating, beating areas spontaneously form within these “embryoid bodies” (EBs). From these areas, individual cardiomyocytes can be dissociated using enzymatic digestion (collagenase); these cardiomyocytes are accessible to functional, molecular-biological and morphological (immune histochemistry, electron microscopy) examination techniques during the various differentiation stages. In addition to cardiomyocytes, the thus generated EBs also include, inter alia, neurons, glia cells, hematopoietic cells, endothelial cells (early capillary), smooth muscle cells, skeletal muscle cells, cartilage cells, fibroblasts and epithelial cells.
- In addition, bioluminescent proteins such as Green Fluorescent Protein (GFP hereinafter) have recently been described (Prasher et al., Gene, Vol. 111, 229-233 (1992)); they are proposed for use as markers in gene expression (Chalfie et al., Science, Vol. 263, 802-805 (1994)). Thus, WO-A-95/07463 and WO-A-96/27675 disclose the transformation of cells with GFP. However, the transformation of mammal cells, especially mammal ES cells, with a DNA sequence coding for GFP has been described neither in this nor in another reference.
- Cardiovascular diseases are still among the most frequent causes of death in the Western industrial countries. Only through intensive basic research in this field, the pathophysiological causes can be found, and new therapeutic approaches can be devised, and toxicological changes described. For studying the pathogenesis of cardiovascular diseases and for testing new pharmacological and toxicological substances, models are needed which, on one hand, can be transferred to humans and, on the other hand, can replace the tedious and cost-intensive animal models. Still in the year 1991, over 2 million animals have been employed for animal experiments in the federal states of the former Western Germany alone.
- One starting point of pharmacological/toxicological research which has recently grown more and more important is heart differentiation. From the stereotypically proceeding heart cell development, conclusions can be drawn to pathological and toxicological changes of cardiomyocytes. Thus, for example, it is known that the receptor state and the intracellular signal cascades are disturbed in cardiac hypertrophy (Yamazaki et al., J. Mol. Cell Cardiol. 27(1): 133-140 (1995)) and heart insufficiency (Johnson et al., Biochem. Pharmacol. 45(12): 2365-2372 (1993)). These pathologically altered cardiomyocytes are in part again similar to heart cells of early differentiation stages.
- However, the examinations necessary for elucidating the properties of heart cells in early differentiation stages are technically difficult to perform with live animals and, if they can be performed at all, it is only in very complicated studies. On day 12-13, at the earliest, it is possible to prepare cardiomyocytes from a murine embryo, but such cells no longer correspond to an early cardiac differentiation stage. A detailed analysis of receptor expression during various differentiation stages requires a very high expense of animal material and is technically difficult to perform as set forth above. Similarly, the observation of the development of a relatively undifferentiated heart cell over several days or weeks is not possible with an animal model. In order to test the use of novel therapeutical agents, e.g., inotropic substances or antiarrhythmics or toxical substances, e.g., heavy metals or retinoids, an invasive monitoring of animals, e.g., swine, must be performed for weeks in animal experiments.
- Now, it has been the object of the present invention to provide a cell culturing method which enables a simple characterization of the living cells and allows for functional examinations rather than being based on reporter genes such as Lac-Z (Niwa et al., 1991, Gene 108, 193-199; Wobus et al., 1996, J. Cell Mol. Cardiol.; Metzger et al., 1996, Circ. Res., 78, 547-552), as with prior methods, the expression of which genes can be detected only after cell fixation and by means of a specific substrate.
- Surprisingly, it has been found that ES cells can be stably transfected, using electroporation, with a DNA construct in which a gene coding for a non-cell-damaging fluorescent protein is coupled with a cell- and development-dependent promoter. This construct is integrated in the native DNA. After the specific activation of intracellular signals, the promoter is activated and the fluorescent protein expressed. Thus, ES cells which activate a cell-specific transcription factor at a certain point of differentiation could be recognized by their fluorescence emissions when being under fluorescent excitation.
- Thus, the present invention relates to non-human mammal embryonic stem (ES) cells stably transfected with a DNA construct comprising
-
- a DNA sequence coding for a non-cell-damaging fluorescent protein; and
- a cell- and/or development-dependent promoter operably linked with said DNA sequence.
- The ES cells are preferably derived from rodents, especially mice. Particularly preferred ES cells are D3 cells (Doetschmann et al., J. Embryol. Exp. Morphol. 87, 27 (1985)), R1 cells (Nagy et al., PNAS (1995)), E14 cells (Handyside et al., Roux Arch. Develop. Biol. 198, 48 (1989)), CCE cells (Bradley et al., Nature 309, 255 (1985)) and P19 cells (Mummery et al., Dev. Biol. 109, 402 (1985)).
- As the “non-cell-damaging fluorescent protein” according to the present invention, there may be used the Green Fluorescent Protein (GFP) from the jellyfish Auequorea victoria (described in WO-A-95/07463, WO-A-96/27675 and WO-A-95/21191) and its derivatives “Blue GFP” (Heim et al., Curr. Biol. 6(2): 178-182 (1996)) and “Redshift GFP” (Muldoon et al.; Biotechniques 22(1): 162-167 (1997)). Preferred is the green fluorescent GFP, especially the GFP mutant contained in the deposited strain DSM 11633.
- According to the present invention, the term “cell- and/or development-dependent promoter” is intended to mean a promoter which displays its promoter activity only in particular cell types and/or only in particular stages of cellular development, both in cell cultures (embryoid bodies) and in transgenic non-human mammals dervied from the ES cells according to the invention. In addition, any other known cell-specific promoter can be employed, e.g., for nerve cells, heart cells, neurons, glia cells, hematopoietic cells, endothelial cells, smooth muscle cells, skeletal muscle cells, cartilage cells, fibroblasts and epithelial cells.
- In a preferred embodiment of the invention, the promoter is a promoter specific for heart cells. In particular, the following promoters may be mentioned: SMHC Minimal Promoter (specific for smooth muscle cells, Kallmeier et al., J. Biol. Chem. 270(52): 30949-30957 (1995)); Nkx-2.5 (specific for very early cardiomyocytes, Lints et al., Development, 119(2): 419-431 (1993)); human α-actin (specific for cardiac tissue, Sartorelli et al., Genes Dev., 4(10): 1811-1822 (1990)); MLC-2V (specific for ventricles, O'Brien et al., Proc. Natl. Acad. Sci. USA, 90(11): 5157-5161 (1993) and WO-A-96/16163.
- In a preferred embodiment, the DNA construct includes further functional DNA sequences, especially enhancers and selective sequences. Such selective sequences include, e.g., neomycin and hygromycin.
- The invention further relates to a method for preparing the ES cells according to the invention, comprising:
-
- introducing a DNA construct as defined above in starting ES cells of non-human mammals; and
- screening for stably transfected ES cells.
- Said introducing may be effected by any method known to those skilled in the art. However, electroporation is preferred. The screening is preferably performed using the selective sequences present in the DNA construct.
- The invention also relates to the above described DNA construct. Preferred constructs are the reporter constructs pCX-(β-act)GFP-Neo and pCX-(α-act)GFP-Neo (DSM 11633) as depicted in
FIGS. 1 and 2 . - The invention also relates to a cell culture exhibiting cell-type specific expression of a non-cell-damaging fluorescent protein, obtainable by culturing the ES cells according to the invention. In a preferred embodiment, the cells are in the form of aggregates (embryoid bodies). In the preparation of the embryoid body, standard methods are followed, e.g., the “hanging drop” method or methylcellulose culture (Wobus et al., Differentiation (1991) 48, 172-182).
- These cell cultures can be used in methods for the toxicological examination of substances, e.g., retinoids, heavy metals and pharmaceutical agents. They have substantial advantages over any cell culture models used to date:
-
- a) The living, unfixed cells can be observed while differentiating; thus, for example, the growth of the heart cells can be continuously observed in the beating area.
- b) Cells in an early stage of development can be made accesible to electrophysiological and other measuring methods because, being fluorescent cells, they are easily discerned (see
FIG. 3 ). This means an essential simplification of the functional study of these cells. - c) A single cell preparation implies a loss of cells. To visualize the small number of the cells still present, the cells expressing the fluorescent protein are advantageous. The method can be complemeted with a FACS sorting method whereby homogeneous cell populations can be obtained. Thus, it is also possible to perform studies (e.g., molecular-biological ones) with a larger population of phenotypically differentiated ES cells.
- d) Since the ES cells expressing the fluorescent protein become visible in the EB upon activation of heart-specific promoters, the growth of the heart-related cells can be determined under pharmacological/toxicological conditions by a quite simple method. For routine examinations of the effect of different substances on heart cell differentiation, the area of cells expressing fluorescent protein in the EB could be determined at different times, and thus it could be established whether these substances quantitatively or qualitatively influence the differentiation of heart cells. For quantitatively more precise results, the cells could be dissociated and then subjected to the FACS sorting technique (
FIG. 4 ).
- Finally, the invention relates to
- a method for producing transgenic non-human mammals exhibiting cell-type specific expression of a non-cell-damaging fluorescent protein, comprising:
- injecting ES cells according to the invention into blastocysts of non-human mammals; and
- transferring the blastocysts into surrogate mothers;
- transgenic non-human mammals obtainable by said method; and a method for examining stages of development of cells of non-human mammals, comprising the examination of the correspondingly marked cells of non-human mammals according to the invention using fluorimetric methods.
- By the examination method according to the invention, an exact cell typing can be performed for the first time in vivo in the whole animal. Thus, fluorescent heart cells should be observed already in the early primordiums of the embryos, which would enable an in vivo observation of the development of the heart in the early embryonic stage. Also, the heart cells could be easily identified thereby in different stages of development.
- The invention will be further illustrated by the following Figures and Examples.
-
FIG. 1 shows the reporter gene construct pCX-(β-act)GFP-Neo used in Example 1. -
FIG. 2 shows the reporter gene construct pCX-(α-act)GFP-Neo (DSM 11633) used in Example 2. -
FIG. 3 , Part A: Two young EBs are shown in suspension under transmitted light (Aa) and under 488 nm excitation (Ab). Since heart cells have not yet differentiated in these early EBs, a green fluorescence cannot be seen. - Part B: EB after 3 days of plating (7+3 days) under transmitted light (Ba), under 488 nm fluorescence excitation (Bb) and in a combination of transmitted light and 488 nm fluorescence excitation. In this EB, a relatively small spontaneously beating area could be observed. This corresponds to the portion of the EB exhibiting spontaneous contractions. The EBs were imaged with 20× magnification.
-
FIG. 4 FIG. 4 shows distribution histograms of cells from EBs established by the FACS method, obtained from ES cells with pCX-(α-act)GFP-Neo. The construct was linearized using AatI so that the CMV-IE enhancer was destroyed. - (a) ES cells
- (b) after 2 days of suspension (2+2 days)
- (c) 5 days after plating (7+5 days)
- x axis: intensity of GFP fluorescence (FACS units), y axis: cell counts.
- Preparation of stable ES cell lines expressing GFP under a strong ubiquitous promoter, and differentiation and properties of cardiomyocytes derived from these cells.
- a) Preparation of the GFP expression construct: The pCX GFP expression vector supplied by Dr. Okabe (University of Osaka, Japan) which contains a GFP-coding sequence under a chicken a-actin promoter (M. Ikawa, K. Kominami, Y. Yoshimura, K. Tanaka, Y. Nishimune and M. Okabe, Develop. Growth Differ. (1995) 37, 455-459) was modified as follows:
- A SalI-XbaI restriction fragment containing a neomycin (G418) resistance gene of pTL2Neo (supplied by Dr. Tarakhovsky) was inserted into the SalI site of pCX-GFP by ligation with blunt ends. The resulting construct pCX-(β-act)GFP-Neo (
FIG. 1 ) was used for the electroporation of D3 cells. - b) Electroporation and selection procedure: The pCX-(β-act)GFP-Neo construct was linearized with restrictase ScaI (outside the GFP expression cassette) and used for the electroporation of the D3 line of ES cells under the following conditions:
- DNA: 20-40 μg, cells: 7×10/ml in 0.8 ml PBS buffer, electroporation cuvete BioRad 0.4 cm (Cat. No. 165-2088), electroporation appratus BioRad (Gen Pulser), 240 V, 500 μF.
- After the electroporation, the cell suspension was placed on ice for 20 min and then transferred to a 10 cm tissue grade Petri dish with a G418 resistance feeder layer in 10 ml of DMEM medium with 15% FCS (fetal calf serum). Two days later, 300 μg/ml neomycin (G418, Gibco) was added to select G418-resistant cells. The medium with G418 (300 μg/ml) was exchanged every other day. After 8 to 10 days of selection, drug-resistant colonies appeared which were tested for GFP expression by fluorescence microscopy.
- About 95% of the G418-resistant colonies exhibited a strong GFP expression (green luminosity), indicating a high degree of activity of the β-actin promoter (β-actin is one of the main proteins of the cytoskeleton) in ES cells. The colonies were taken up by sucking with a Pasteur pipette, individually trypsinized and subsequently transferred to 48- and 24-well plates with feeder layers with G418 (300 μg/ml) for proliferation. Finally, several stable ES clones bearing 1 to 5 copies of the GPS gene under the control of the chicken β-actin promoter were detected and used for the production of embryoid bodies (EBs).
- c) Differentiation and analysis of the cardiomyocytes: EBs were developed according to the standard “hanging drop” method (A. Wobus, G. Walluka and J. Hescheler; Differentiation (1991) 48, 173-182).
- In all stages of development prior to plating, the EBs derived from ES cells having an integrated GFP expression vector under the control of the M-actin promoter exhibited an intense green luminosity under the fluorescence microscope. After plating, the GFP expression was distributed in unequal proportions among different cell types which appeared in the course of differentiation. The brightest green luminosity in EBs after the occurrence of contractile myocardiocytes coincides with corresponding beating regions rathr than beating core parts (central parts) of EBs.
- Other regions of the EBs show different degrees of GFP expression from weak to strong which indicates the well-known wide -spread expression of β-actin as a main component of the cytoskeleton in various cell types.
- These visual observations are confirmed by histograms of the distribution of GFP expression in the cell populations in the developing EBs, obtained by FACS analysis (flow cytofluorimetry). They show the left-hand shift and enlargement of initially sharp symmetrical peaks of the histogram, which indicates a transition from a high and relatively homogeneous GFP expression in a population of proliferating undifferentiated ES cells to a broad distribution of the same among the population of differentiating cell types.
- EBs were differentiated using collagenase and plated onto slides and then cultured for 2-3 days after which electrophysiological measurements were made according to the standard procedure (V. Maltsev, A. Wobus, J. Rohwedei, M. Bader and J. Hescheler, Circ. Res. (1994) 75(2), 233-244).
- Isolated spontaneously beating cardiomyocytes which strongly express GFP have all the electrophysiological properties typical of cardiomyocytes including action potentials, Ca2+, Na+, K+ and If flows, which was shown by the patch-clamp technique.
- Thus, stable ES cell lines which are strongly expressing GFP due to an expression vector integrated in the genome can differentiate into functionally mature contractile cardiomyocytes which have the same basic electro-physiological properties as cardiomyocytes which have differentiated from “normal” D3 cells.
- Preparation of stable ES cell lines expressing GFP under a heart-specific promoter in differentiating cardiomyocytes.
- a) Preparation of the GFP expression construct: From the plasmid pPv/B-Act-lacZ supplied by Dr. M. McBurney (University of Ottawa, Canada) which contained the segment (−440+6) of the heart-specific human α-actin promoter (A. Minti, L. Kedes; Molecular and Cellular Biology (1986) 6, 2125-2136; G. Pari, K. Jardine and M. McBurney; Molecular and Cellular Biology (1991) 11, 4795-4803), the promoter was excised using the restriction enzymes SalI and HindIII. In order to replace the chicken β-actin promoter by the heart-specific α-actin promoter, the pCX-GFP expression vector (see Example 1) was cleaved with the restrictases SnaBI and ApaI to excise the chicken β-actin promoter. Subsequently, the above mentioned SalI-HindIII fragment of the heart-specific α-actin promoter was inserted by ligation with blunt ends. The restrictases Tth111I, SalI and HinfI were used to select plasmid clones in which the heart-specific α-actin promoter had been inserted in the right orientation with respect to the GFP-coding sequence. A neomycin (G418) resistance gene as described in Example 1a) was then inserted in the SalI site, and the resulting plasmid pCX-(α-act)GFP-Neo (
FIG. 2 ) was used for the electroporation of D3 cells. - b) Electroporation and selection procedure: The pCX-(α-act)GFP-Neo was linearized with ScaI (outside the GFP expression cassette, as described in Example 1b)) or AatI to destroy the cytomegalovirus (CMV-IE) enhancer (see below). The electroporation and the G418 selection procedure were performed as described in Example 1b).
- c) Analysis of the cell population and GFP expression under the control of the heart-specific α-actin promoter during the differentiation of cardiomyocytes: EBs were developed as described in Example 1c). In contrast to the above described patterns of GFP expression under the control of the β-actin promoter, ES cells bearing the pCX-(α-act)GFP-Neo integrated in the genome exhibit no or only a very weak signal which is visible by fluorescence microscopy. The FACS analysis shows that the average level of the green fluorescence of D3 cells containing pCX-(α-act)GFP-Neo linearized by SacI is about 35 to 40 times lower than for cell lines bearing pCX-(β-act)-GFP-Neo. During the development of the EBs, a right-hand shift and enlargement of the initial peak of the GFP fluorescence histogram obtained by FACS was seen. The beating regions which occurred 2 to 4 days after plating the EBs show a green luminosity visible by fluorescence microscopy at a level comparable to that of the GFP expression in ES cells bearing pCX-(β-act)GFP-Neo. Perhaps, the beating regions consisting of functionally mature cardiotyocytes are merely regions having an intense visible luminosity among other cell types in developing EBs. By daily monitoring, it is possible to detect separated luminous regions 1 to 1.5 days before they start to beat.
- The heart-specific character of GFP expression was confirmed by α-actin specific immunostaining of single cells, which correlates with the GFP expression under the control of the heart-specific α-actin promoter.
- d) Preparation of ES cell lines having a low initial non-specific level of GFP expression: The above mentioned ES clones with integrated pCX-(α-act)-GFP-Neo showed unambiguous cardiomyocyte-specific expression patterns which resulted in an evident coincidence of luminous and beating regions. However, the initial level of the GFP expression of these undifferentiated cells which is 5 to 10 times higher than for a negative control (intact ES cells) could impede the detection of the cells in the very first stages of differentiation.
- In order to lower the initial level of non-specific GFP expression, a number of new cell lines were generated using pCX-(α-act)GFP-Neo linearized with AatI restrictase (
FIG. 2 ) to enable destruction of the CMV-IE enhancer. - The latter was present in the original expression vector, and it was assumed that this was the reason for the initial non-specific “background”.
- After electroporation and the selection procedure, the G418-resistant clones showed a much higher diversification of the initial GFP expression than was shown by clones with an intact CMV-IE enhancer. Several ES clones with the lowest “background” were selected by FACS screening. These clones have an about 5 times lower initial fluorescence intensity and may be comparable with cells of the negative control (wild type) without a GFP vector. After the preparation of EBs from corresponding ES cell clones, some of them showed GFP expression in differentiating cardiomyocytes which was detectable both by fluorescence microscopy and by FACS analysis. The FACS analysis exhibited a high resolution between cells having entered heart-specific differentiation and the remainder of the cell population which showed, the pronounced one-to-two peak character of histogram dynamics during the EB development (
FIG. 4 ). - Thus, the described approach allows to examine the differentiation of ES cells into cardiomyocytes “in vitro”, the GFP expression vector with the heart-specific promoter being used as a “living” reporter-gene system which renders cells in the early stages of development discernible.
- The above described plasmid pCX-(α-act)GFP-Neo has been deposited on Jun. 27, 1997, with the Deutsche Sammiung von Mikroorganismen und Zellkulturen GmbH, Maschroder Weg 1b, D-38124 Braunschweig, under the designation of DSM 11633.
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/293,932 US20060168665A1 (en) | 1997-07-02 | 2005-12-05 | Flourescent proteins as cell type specific reporters |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19727962A DE19727962A1 (en) | 1997-07-02 | 1997-07-02 | Fluorescent proteins as cell type-specific reporters |
DEDE19727962.7 | 1997-07-02 | ||
PCT/EP1998/003988 WO1999001552A1 (en) | 1997-07-02 | 1998-06-30 | Fluorescent proteins as cell-type specific reporter |
US44671700A | 2000-04-13 | 2000-04-13 | |
US10/084,960 US7105344B2 (en) | 1997-07-02 | 2002-02-28 | Fluorescent proteins as cell-type specific reporters |
US11/293,932 US20060168665A1 (en) | 1997-07-02 | 2005-12-05 | Flourescent proteins as cell type specific reporters |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/084,960 Division US7105344B2 (en) | 1997-07-02 | 2002-02-28 | Fluorescent proteins as cell-type specific reporters |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060168665A1 true US20060168665A1 (en) | 2006-07-27 |
Family
ID=7834239
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/084,960 Expired - Lifetime US7105344B2 (en) | 1997-07-02 | 2002-02-28 | Fluorescent proteins as cell-type specific reporters |
US11/293,932 Abandoned US20060168665A1 (en) | 1997-07-02 | 2005-12-05 | Flourescent proteins as cell type specific reporters |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/084,960 Expired - Lifetime US7105344B2 (en) | 1997-07-02 | 2002-02-28 | Fluorescent proteins as cell-type specific reporters |
Country Status (9)
Country | Link |
---|---|
US (2) | US7105344B2 (en) |
EP (1) | EP1002080B9 (en) |
JP (1) | JP3956154B2 (en) |
AT (1) | ATE234357T1 (en) |
DE (2) | DE19727962A1 (en) |
DK (1) | DK1002080T3 (en) |
ES (1) | ES2191324T3 (en) |
PT (1) | PT1002080E (en) |
WO (1) | WO1999001552A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040096432A1 (en) * | 2000-12-27 | 2004-05-20 | Bernd Fleischmann | System for the cell-specific and development-specific selection of differentiating embryonic stem cells, adult stem cells and embryonic germline cells |
US20070258948A1 (en) * | 2003-06-20 | 2007-11-08 | Axiogenesis Ag | Tissue Modeling in Embryonic Stem (Es) Cell System |
US20080019952A1 (en) * | 2003-07-08 | 2008-01-24 | Axiogenesis Ag | Novel Method for the Preparation of Embryoid Bodies (Ebs) and Uses Thereof |
US20080132422A1 (en) * | 2004-04-07 | 2008-06-05 | Axiogenesis Ag | Non-Invasive, In Vitro Functional Tissue Assay Systems |
US20090328243A1 (en) * | 2003-07-08 | 2009-12-31 | Andreas Ehlich | Secreted proteins as markers for cell differentiation |
US8318488B1 (en) | 2004-05-11 | 2012-11-27 | Axiogenesis Ag | Assay for drug discovery based on in vitro differentiated cells |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19727962A1 (en) * | 1997-07-02 | 1999-01-14 | Juergen Hescheler | Fluorescent proteins as cell type-specific reporters |
US7410798B2 (en) | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
CN1411470A (en) * | 1999-11-19 | 2003-04-16 | 冷泉港实验室 | Transgenic mice expressing fluorescent protein |
US7455983B2 (en) | 2000-01-11 | 2008-11-25 | Geron Corporation | Medium for growing human embryonic stem cells |
GB0014009D0 (en) * | 2000-06-08 | 2000-08-02 | Devgen Nv | Compound screens relating to insulin deficiency or insulin resistance |
US6576464B2 (en) | 2000-11-27 | 2003-06-10 | Geron Corporation | Methods for providing differentiated stem cells |
DE10136702B4 (en) | 2000-12-27 | 2004-04-22 | Axiogenesis Ag | System for cell and development specific selection of differentiating embryonic stem cells, adult stem cells and embryonic germline cells |
CA2441571A1 (en) * | 2001-03-20 | 2002-09-26 | University Of Virginia Patent Foundation | Methods for identifying and purifying smooth muscle progenitor cells |
CN1671860A (en) * | 2002-07-26 | 2005-09-21 | 威斯康星校友研究基金会 | Functional cardiomyocytes from human embryonic stem cells |
US20060281136A1 (en) * | 2003-05-20 | 2006-12-14 | Shinichi Nishikawa | Preparation of endodermal stem cells |
US20060292694A1 (en) * | 2005-06-22 | 2006-12-28 | Roslin Institute | Reporter hepatocytes and other cells for drug screening and toxicity testing |
CA2613529A1 (en) * | 2005-06-22 | 2007-01-04 | Geron Corporation | Reporter hepatocytes and other cells for drug screening and toxicity testing |
US20060292695A1 (en) * | 2005-06-22 | 2006-12-28 | Roslin Institute | Methods and kits for drug screening and toxicity testing using promoter-reporter cells derived from embryonic stem cells |
WO2011118655A1 (en) * | 2010-03-23 | 2011-09-29 | オリンパス株式会社 | Method for monitoring state of differentiation in stem cells |
ITPI20100085A1 (en) | 2010-07-07 | 2012-01-08 | Sara Migliarini | PROCEDURE FOR GENETIC ENGINEERING OF STEM CELLS ACTIVATING A VITAL FLUORESCENT TRAILER FOLLOWING THE VITRO DIFFERENTIATION OF THE CELLS ITSELF TO THE SPECIFIC CELL TYPE OF SEROTONINERGIC NEURONS. |
JP2014176364A (en) * | 2013-03-15 | 2014-09-25 | Olympus Corp | Analysis method of stem cells |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040096432A1 (en) * | 2000-12-27 | 2004-05-20 | Bernd Fleischmann | System for the cell-specific and development-specific selection of differentiating embryonic stem cells, adult stem cells and embryonic germline cells |
US7105344B2 (en) * | 1997-07-02 | 2006-09-12 | Axiogenesis Ag | Fluorescent proteins as cell-type specific reporters |
US20070258948A1 (en) * | 2003-06-20 | 2007-11-08 | Axiogenesis Ag | Tissue Modeling in Embryonic Stem (Es) Cell System |
US20080019952A1 (en) * | 2003-07-08 | 2008-01-24 | Axiogenesis Ag | Novel Method for the Preparation of Embryoid Bodies (Ebs) and Uses Thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2281648A1 (en) * | 1997-02-13 | 1998-08-20 | Memorial Sloan-Kettering Cancer Center | Hybrid molecules for optically detecting changes in cellular microenvironments |
-
1997
- 1997-07-02 DE DE19727962A patent/DE19727962A1/en not_active Ceased
-
1998
- 1998-06-30 DK DK98940092T patent/DK1002080T3/en active
- 1998-06-30 JP JP50631699A patent/JP3956154B2/en not_active Expired - Lifetime
- 1998-06-30 EP EP98940092A patent/EP1002080B9/en not_active Expired - Lifetime
- 1998-06-30 PT PT98940092T patent/PT1002080E/en unknown
- 1998-06-30 WO PCT/EP1998/003988 patent/WO1999001552A1/en active IP Right Grant
- 1998-06-30 AT AT98940092T patent/ATE234357T1/en active
- 1998-06-30 ES ES98940092T patent/ES2191324T3/en not_active Expired - Lifetime
- 1998-06-30 DE DE59807479T patent/DE59807479D1/en not_active Expired - Lifetime
-
2002
- 2002-02-28 US US10/084,960 patent/US7105344B2/en not_active Expired - Lifetime
-
2005
- 2005-12-05 US US11/293,932 patent/US20060168665A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7105344B2 (en) * | 1997-07-02 | 2006-09-12 | Axiogenesis Ag | Fluorescent proteins as cell-type specific reporters |
US20040096432A1 (en) * | 2000-12-27 | 2004-05-20 | Bernd Fleischmann | System for the cell-specific and development-specific selection of differentiating embryonic stem cells, adult stem cells and embryonic germline cells |
US20070258948A1 (en) * | 2003-06-20 | 2007-11-08 | Axiogenesis Ag | Tissue Modeling in Embryonic Stem (Es) Cell System |
US20080019952A1 (en) * | 2003-07-08 | 2008-01-24 | Axiogenesis Ag | Novel Method for the Preparation of Embryoid Bodies (Ebs) and Uses Thereof |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040096432A1 (en) * | 2000-12-27 | 2004-05-20 | Bernd Fleischmann | System for the cell-specific and development-specific selection of differentiating embryonic stem cells, adult stem cells and embryonic germline cells |
US20070258948A1 (en) * | 2003-06-20 | 2007-11-08 | Axiogenesis Ag | Tissue Modeling in Embryonic Stem (Es) Cell System |
US9321997B2 (en) | 2003-06-20 | 2016-04-26 | Axiogenesis Ag | Tissue modeling in embryonic stem (ES) cell system |
US20080019952A1 (en) * | 2003-07-08 | 2008-01-24 | Axiogenesis Ag | Novel Method for the Preparation of Embryoid Bodies (Ebs) and Uses Thereof |
US20090328243A1 (en) * | 2003-07-08 | 2009-12-31 | Andreas Ehlich | Secreted proteins as markers for cell differentiation |
US8148152B2 (en) | 2003-07-08 | 2012-04-03 | Axiogenesis Ag | Method for the preparation of embryoid bodies (EBs) and uses thereof |
US20080132422A1 (en) * | 2004-04-07 | 2008-06-05 | Axiogenesis Ag | Non-Invasive, In Vitro Functional Tissue Assay Systems |
US9945840B2 (en) | 2004-04-07 | 2018-04-17 | Axiogenesis Ag | Non-invasive, in vitro functional tissue assay systems |
US11835433B2 (en) | 2004-04-07 | 2023-12-05 | Evotec International Gmbh | Non-invasive, in vitro functional tissue assay systems |
US8318488B1 (en) | 2004-05-11 | 2012-11-27 | Axiogenesis Ag | Assay for drug discovery based on in vitro differentiated cells |
US9726662B2 (en) | 2004-05-11 | 2017-08-08 | Axiogenesis Ag | Assay for drug discovery based on in vitro differentiated cells |
Also Published As
Publication number | Publication date |
---|---|
ATE234357T1 (en) | 2003-03-15 |
EP1002080A1 (en) | 2000-05-24 |
EP1002080B9 (en) | 2004-08-11 |
DE59807479D1 (en) | 2003-04-17 |
WO1999001552A1 (en) | 1999-01-14 |
DK1002080T3 (en) | 2003-05-26 |
EP1002080B1 (en) | 2003-03-12 |
JP2002508670A (en) | 2002-03-19 |
US20020092035A1 (en) | 2002-07-11 |
PT1002080E (en) | 2003-06-30 |
US7105344B2 (en) | 2006-09-12 |
JP3956154B2 (en) | 2007-08-08 |
DE19727962A1 (en) | 1999-01-14 |
ES2191324T3 (en) | 2003-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060168665A1 (en) | Flourescent proteins as cell type specific reporters | |
JP4891884B2 (en) | A system for cell-specific and growth-specific selection of differentiating embryonic stem cells, adult stem cells and embryonic germline cells | |
Klug et al. | DNA synthesis and multinucleation in embryonic stem cell-derived cardiomyocytes | |
Zweigerdt et al. | Generation of confluent cardiomyocyte monolayers derived from embryonic stem cells in suspension: a cell source for new therapies and screening strategies | |
Salminen et al. | Efficient poly A trap approach allows the capture of genes specifically active in differentiated embryonic stem cells and in mouse embryos | |
US9994822B2 (en) | Cardiomyocyte differentiation | |
US20070161107A1 (en) | Differentiation of human embryonic stem cells to cardiomyocytes | |
Hancock et al. | Neuronal differentiation of cryopreserved neural progenitor cells derived from mouse embryonic stem cells | |
KR20070007120A (en) | Rat embryonic stem cell | |
Ekberg et al. | OMP-ZsGreen fluorescent protein transgenic mice for visualisation of olfactory sensory neurons in vivo and in vitro | |
Becker et al. | A Role forIndian hedgehogin Extraembryonic Endoderm Differentiation in F9 Cells and the Early Mouse Embryo | |
Moore et al. | A P19Cl6 GFP reporter line to quantify cardiomyocyte differentiation of stem cells. | |
JPWO2004104184A1 (en) | Preparation of endoderm stem cells | |
CA2502250A1 (en) | Methods using gene trapped stem cells for marking pathways of stem cell differentiation and making and isolating differentiated cells | |
JP2002065261A (en) | Method for obtaining reproductive cell | |
Adams et al. | Double lox targeting for neural cell transgenesis | |
JP2002051775A (en) | Method for concentrating and separating dopaminergic neuron | |
Sinha et al. | Derivation of contractile smooth muscle cells from embryonic stem cells | |
Shirzad et al. | Production of stable GFP-expressing neural cells from P19 embryonal carcinoma stem cells | |
Baharvand et al. | Differentiation of embryonic stem cells into functional neurons in vitro | |
Arnhold et al. | GFP labelled ES cell derived neural precursor cells differentiate into Thy-1 positive neurons and glia after transplantation into the striatum of the adult rat striatum | |
Hung et al. | Zebrafish synuclein gamma b promoter directs GFP expression in zebrafish notochord. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AXIOGENESIS, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HESCHELER, JURGEN;REEL/FRAME:017693/0414 Effective date: 20060323 |
|
AS | Assignment |
Owner name: AXIOGENESIS AG, GERMANY Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA NAME AND ADDRESS INFORMATION PREVIOUSLY RECORDED ON REEL 017693 FRAME 0414;ASSIGNOR:HESCHELER, JURGEN;REEL/FRAME:020015/0957 Effective date: 20060323 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |